Case Studies

Challenge: A public, multi-national pharmaceutical company historically focused on producing generics (including branded), active pharmaceuticals ingredients, biologics, and over the counter...

Challenge: An early-stage biotechnology company with several assets in pre-clinical development for CNS diseases wanted to supplement its internal pipeline with external innovation. The company...

Challenge A European clinical-stage biopharma company was developing a recombinant protein for multiple immune-driven indications and required support in shaping its future business strategy....

Challenge: Our client was advising principal investors on a possible transaction to cover the development and commercialization of a product targeting chemotherapy-induced anemia (CIA). Alacrita was...

Challenge: A UK investment company was considering leading an investment round in a UK-based platform technology company utilizing induced pluripotent stem cells (iPSCs) in disease models as R&D...

Challenge: An early-stage biotechnology startup company reached out to Alacrita for critical support of its two lead AAV-delivered gene therapy programs. As a virtual company, the client needed...

Challenge A European company developing novel antiviral drugs urgently needed an experienced pharmaceutical physician to work as an interim CMO, as the predecessor was about to move into a leadership...

Challenge A European investor was refocusing its investment efforts and considering targeting the oncology cell therapy space. It had a particular interest in tumor infiltrating lymphocytes (TILs)...

Challenge A pharma investor client joined a European animal health company and asked Alacrita to conduct a strategic review, in the light of urgent business needs. The entire sector had been through...

Challenge Our client was a privately-held US biotech company developing a proprietary platform technology for in vivo expression of DNA coding for a therapeutic antibody or protein. The approach...

Challenge: Our client, a PE-backed specialty pharma company growing rapidly through M&A, was assessing a number of late-stage development projects to license/acquire. The asset in question was a...

Challenge One of the leading medical imaging companies worldwide approached Alacrita to assess an opportunity to acquire the manufacturing and distribution rights to an important imaging agent used...